Transitional States in Ligand-Dependent Transformation of the Aryl Hydrocarbon Receptor into Its DNA-Binding Form.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Apr 2020
Historique:
received: 06 03 2020
revised: 20 03 2020
accepted: 30 03 2020
entrez: 8 4 2020
pubmed: 8 4 2020
medline: 29 12 2020
Statut: epublish

Résumé

The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the biological and toxicological effects of an AhR lacking the entire PASB structurally diverse chemicals, including halogenated aromatic hydrocarbons. Ligand-dependent transformation of the AhR into its DNA binding form involves a ligand-dependent conformational change, heat shock protein 90 (hsp90), dissociation from the AhR complex and AhR dimerization with the AhR nuclear translocator (ARNT) protein. The mechanism of AhR transformation was examined using mutational approaches and stabilization of the AhR:hsp90 complex with sodium molybdate. Insertion of a single mutation (F281A) in the hsp90-binding region of the AhR resulted in its constitutive (ligand-independent) transformation/DNA binding in vitro. Mutations of AhR residues within the Arg-Cys-rich region (R212A, R217A, R219A) and Asp371 (D371A) impaired AhR transformation without a significant effect on ligand binding. Stabilization of AhR:hsp90 binding with sodium molybdate decreased transformation/DNA binding of the wild type AhR but had no effect on constitutively active AhR mutants. Interestingly, transformation of the AhR in the presence of molybdate allowed detection of an intermediate transformation ternary complex containing hsp90, AhR, and ARNT. These results are consistent with a stepwise transformation mechanism in which binding of ARNT to the liganded AhR:hsp90 complex results in a progressive displacement of hsp90 and conversion of the AhR into its high affinity DNA binding form. The available molecular insights into the signaling mechanism of other Per-ARNT-Sim (PAS) domains and structural information on hsp90 association with other client proteins are consistent with the proposed transformation mechanism of the AhR.

Identifiants

pubmed: 32252465
pii: ijms21072474
doi: 10.3390/ijms21072474
pmc: PMC7177239
pii:
doi:

Substances chimiques

AHR protein, human 0
Basic Helix-Loop-Helix Transcription Factors 0
DNA-Binding Proteins 0
HSP90 Heat-Shock Proteins 0
Ligands 0
Receptors, Aryl Hydrocarbon 0
Molybdenum 81AH48963U
DNA 9007-49-2
sodium molybdate(VI) 948QAQ08I1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : R01-ES007685
Pays : United States

Références

Chem Res Toxicol. 2008 Jan;21(1):102-16
pubmed: 18076143
Biochemistry. 2013 Jan 29;52(4):714-25
pubmed: 23286227
Annu Rev Pharmacol Toxicol. 2003;43:309-34
pubmed: 12540743
Arch Biochem Biophys. 1991 Dec;291(2):284-90
pubmed: 1659322
Annu Rev Immunol. 2014;32:403-32
pubmed: 24655296
Toxicol Sci. 2011 Nov;124(1):1-22
pubmed: 21908767
Biochemistry. 2007 Dec 11;46(49):14001-9
pubmed: 18001137
Mol Cell Biol. 1999 Aug;19(8):5811-22
pubmed: 10409767
Arch Biochem Biophys. 1997 Dec 1;348(1):190-8
pubmed: 9390191
Toxicol Sci. 2008 Nov;106(1):83-92
pubmed: 18660548
Nat Rev Immunol. 2019 Mar;19(3):184-197
pubmed: 30718831
Curr Protoc Toxicol. 2002 May;Chapter 4:Unit4.8
pubmed: 20945300
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8566-70
pubmed: 8397410
Biochem Mol Biol Int. 1996 Jun;39(3):589-93
pubmed: 8828811
EMBO J. 1993 Nov;12(11):4169-79
pubmed: 8223432
J Biol Chem. 1986 Aug 5;261(22):10189-95
pubmed: 3015922
J Biol Chem. 2000 Nov 17;275(46):36407-14
pubmed: 10961990
Nature. 2015 Aug 20;524(7565):303-8
pubmed: 26245371
Science. 2016 Jun 24;352(6293):1542-7
pubmed: 27339980
J Biol Chem. 1995 Dec 8;270(49):29270-8
pubmed: 7493958
J Biol Chem. 1998 Jan 30;273(5):2895-904
pubmed: 9446600
Sci Rep. 2019 Jul 23;9(1):10693
pubmed: 31337850
Drug Metab Dispos. 2015 Oct;43(10):1522-35
pubmed: 26041783
Nat Rev Mol Cell Biol. 2017 Jun;18(6):345-360
pubmed: 28429788
BMC Genomics. 2011 Jul 15;12:365
pubmed: 21762485
PLoS Comput Biol. 2018 Feb 28;14(2):e1006021
pubmed: 29489822
Mol Pharmacol. 2000 Jan;57(1):82-92
pubmed: 10617682
J Biol Chem. 2011 Oct 7;286(40):35275-82
pubmed: 21856752
FEBS Open Bio. 2014 Sep 16;4:796-803
pubmed: 25349783
J Biochem. 2018 Mar 1;163(3):223-232
pubmed: 29092071
Mol Pharmacol. 2010 Feb;77(2):247-54
pubmed: 19903824
Biochemistry. 2009 Jun 30;48(25):5972-83
pubmed: 19456125
J Biol Chem. 2008 Nov 21;283(47):32995-3005
pubmed: 18806268
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6252-7
pubmed: 16606854
J Biol Chem. 1988 Nov 25;263(33):17221-4
pubmed: 2846558
Mol Pharmacol. 1992 Oct;42(4):603-12
pubmed: 1331752
Mol Pharmacol. 1993 Sep;44(3):511-8
pubmed: 8396713
Biochem J. 1993 Aug 15;294 ( Pt 1):95-101
pubmed: 8395819
Pharmacol Ther. 2018 May;185:50-63
pubmed: 29258844
Biochemistry. 2005 Mar 29;44(12):4627-35
pubmed: 15779889
Toxicol Sci. 2007 Jul;98(1):99-109
pubmed: 17431010
Curr Opin Toxicol. 2017 Feb;2:124-131
pubmed: 28845473
J Biol Chem. 1995 Oct 20;270(42):25291-300
pubmed: 7559670
Toxicol Lett. 2013 Oct 23;223(1):52-9
pubmed: 23994337
J Biol Chem. 1997 Dec 12;272(50):31845-54
pubmed: 9395531
J Mol Biol. 2008 Mar 21;377(2):512-23
pubmed: 18258261
EMBO J. 1995 Jul 17;14(14):3528-39
pubmed: 7628454
Pharmacol Rev. 2015;67(2):259-79
pubmed: 25657351
Environ Health Perspect. 1994 Nov;102 Suppl 9:157-67
pubmed: 7698077
Toxicol Appl Pharmacol. 1996 Sep;140(1):173-9
pubmed: 8806883
J Biol Chem. 1996 Feb 16;271(7):3743-9
pubmed: 8631989
Mol Biosyst. 2017 May 2;13(5):981-990
pubmed: 28393157
Mol Pharmacol. 1994 Nov;46(5):915-21
pubmed: 7969080
Structure. 2009 Oct 14;17(10):1282-94
pubmed: 19836329
Phys Chem Chem Phys. 2019 Mar 20;21(12):6622-6634
pubmed: 30855039
PLoS Comput Biol. 2016 Jun 13;12(6):e1004981
pubmed: 27295348
Mol Cell Biol. 1994 Dec;14(12):8343-55
pubmed: 7969169
J Chem Inf Model. 2011 Nov 28;51(11):2868-81
pubmed: 21981577

Auteurs

Anatoly A Soshilov (AA)

Department of Environmental Toxicology, University of California, Davis, CA 95616, USA.

Stefano Motta (S)

Department of Earth and Environmental Sciences, University of Milano-Bicocca, 20126 Milan, Italy.

Laura Bonati (L)

Department of Earth and Environmental Sciences, University of Milano-Bicocca, 20126 Milan, Italy.

Michael S Denison (MS)

Department of Environmental Toxicology, University of California, Davis, CA 95616, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH